M B Lens1, M Dawes, J A Newton-Bishop, T Goodacre. 1. University of Oxford, Centre for Evidence-Based Medicine, Nuffield Department of Clinical Medicine and Department for Plastic and Reconstructive Surgery, The Oxford Radcliffe NHS Trust, Oxford, UK.
Abstract
BACKGROUND: Sentinel lymph node biopsy (SLNB) is a minimally invasive procedure used accurately to stage nodal basins at risk of occult metastases. There are no data as yet to show a survival benefit from SLNB and its use remains controversial. If Breslow thickness of the tumour correlates well with positive SLNB, it could be used to select patients for SLNB. METHODS: A quantitative systematic review of published studies on SLNB in patients with melanoma available by September 2001 was performed. RESULTS: Twelve studies containing 4218 patients with stage I and II melanoma were identified; 17.8 (95 per cent confidence interval 16.7 to 19.0) per cent of patients had nodal micrometastases detected by SLNB. The incidence of micrometastasis in sentinel nodes correlated directly with Breslow tumour thickness; it was 1.0 per cent for lesions of less than or equal to 0.75 mm, 8.3 per cent for 0.76-1.50 mm, 22.7 per cent for 1.51-4.0 mm and 35.5 per cent for more than 4.0 mm. CONCLUSION: The Breslow thickness of primary melanoma predicts the presence of a sentinel node metastasis. The published data are not sufficient to demonstrate a correlation between other known prognostic indicators and a positive SLNB.
BACKGROUND: Sentinel lymph node biopsy (SLNB) is a minimally invasive procedure used accurately to stage nodal basins at risk of occult metastases. There are no data as yet to show a survival benefit from SLNB and its use remains controversial. If Breslow thickness of the tumour correlates well with positive SLNB, it could be used to select patients for SLNB. METHODS: A quantitative systematic review of published studies on SLNB in patients with melanoma available by September 2001 was performed. RESULTS: Twelve studies containing 4218 patients with stage I and II melanoma were identified; 17.8 (95 per cent confidence interval 16.7 to 19.0) per cent of patients had nodal micrometastases detected by SLNB. The incidence of micrometastasis in sentinel nodes correlated directly with Breslow tumour thickness; it was 1.0 per cent for lesions of less than or equal to 0.75 mm, 8.3 per cent for 0.76-1.50 mm, 22.7 per cent for 1.51-4.0 mm and 35.5 per cent for more than 4.0 mm. CONCLUSION: The Breslow thickness of primary melanoma predicts the presence of a sentinel node metastasis. The published data are not sufficient to demonstrate a correlation between other known prognostic indicators and a positive SLNB.
Authors: Annette H Chakera; Birger Hesse; Zeynep Burak; James R Ballinger; Allan Britten; Corrado Caracò; Alistair J Cochran; Martin G Cook; Krzysztof T Drzewiecki; Richard Essner; Einat Even-Sapir; Alexander M M Eggermont; Tanja Gmeiner Stopar; Christian Ingvar; Martin C Mihm; Stanley W McCarthy; Nicola Mozzillo; Omgo E Nieweg; Richard A Scolyer; Hans Starz; John F Thompson; Giuseppe Trifirò; Giuseppe Viale; Sergi Vidal-Sicart; Roger Uren; Wendy Waddington; Arturo Chiti; Alain Spatz; Alessandro Testori Journal: Eur J Nucl Med Mol Imaging Date: 2009-10 Impact factor: 9.236
Authors: Michael S Sabel; John D Rice; Kent A Griffith; Lori Lowe; Sandra L Wong; Alfred E Chang; Timothy M Johnson; Jeremy M G Taylor Journal: Ann Surg Oncol Date: 2011-08-06 Impact factor: 5.344
Authors: A Mitra; C Conway; C Walker; M Cook; B Powell; S Lobo; M Chan; M Kissin; G Layer; J Smallwood; C Ottensmeier; P Stanley; H Peach; H Chong; F Elliott; M M Iles; J Nsengimana; J H Barrett; D T Bishop; J A Newton-Bishop Journal: Br J Cancer Date: 2010-09-21 Impact factor: 7.640
Authors: Melanie A Warycha; Jan Zakrzewski; Quanhong Ni; Richard L Shapiro; Russell S Berman; Anna C Pavlick; David Polsky; Madhu Mazumdar; Iman Osman Journal: Cancer Date: 2009-02-15 Impact factor: 6.860
Authors: Gabriella Liszkay; Gábor Péley; István Sinkovics; Ilona Péter; Zsolt Orosz; Zsuzsa Fejos; Béla Horváth; István Köves; Katalin Gilde; Miklós Kásler Journal: Pathol Oncol Res Date: 2003-10-07 Impact factor: 3.201
Authors: Matthew F Kalady; Rebekah R White; Jeffrey L Johnson; Douglas S Tyler; Hilliard F Seigler Journal: Ann Surg Date: 2003-10 Impact factor: 12.969
Authors: Matthew P Doepker; Zachary J Thompson; Jennifer N Harb; Jane L Messina; Christopher A Puleo; Kathleen M Egan; Amod A Sarnaik; Ricardo J Gonzalez; Vernon K Sondak; Jonathan S Zager Journal: J Surg Oncol Date: 2015-12-10 Impact factor: 3.454